As G-CSF is a potent hematopoiesis stimulating factor (26), higher G-CSF levels in early-onset COVID-19 patients may contribute to protecting the host against infection, preventing the development of lymphopenia observed in severe and fatal COVID-19 cases during the first days from illness onset (27–31). This evidence concerns the gene CSF3 and lymphopenia.